GlassScriptPhysician profile
Gretchen M Sciarrino
NPI 1285673467
$3,766.75
in general payments reported to CMS, 2019-2025
36 companies · $757 in 2025
The $757 reported for 2025 was more than what 93% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,058 · 2022: $973 · 2023: $916 · 2024: $62.77 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,636.02 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378.52 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $377.92 | 2021-2023 | |
| Lilly USA, LLC | $299.94 | 2025 | |
| Lundbeck LLC | $218.86 | 2025 | Vyepti, Rexulti |
| Myovant Sciences INC. | $218.62 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $198.12 | 2023 | Nuplazid |
| Biogen, INC. | $161.41 | 2021 | |
| Astellas Pharma US INC | $155.17 | 2022-2023 | Myrbetriq, Veozah |
| Silk Road Medical, INC. | $145.83 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Hologic Sales and Service, LLC | $137.76 | 2023-2024 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Axsome Therapeutics, INC. | $124.38 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $114.16 | 2025 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $111.12 | 2021 | |
| Novo Nordisk INC | $94.04 | 2021 | |
| Scynexis, INC. | $83.89 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.92 | 2021 | |
| Boston Scientific Corporation | $75.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.55 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.82 | 2022 | |
| Amgen INC. | $70.11 | 2022 | |
| Evofem Biosciences, INC. | $64.92 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $62.88 | 2023 | Myfembree |
| Pfizer INC. | $55.37 | 2022-2023 | |
| Daiichi Sankyo INC. | $53.58 | 2021-2022 | |
| Exeltis, USA INC. | $48.71 | 2022-2023 | Slynd |
| Therapeuticsmd, INC. | $48.09 | 2022 | |
| Mayne Pharma Commercial LLC | $35.70 | 2022 | |
| Axonics, INC. | $34.66 | 2023 | Axonics |
| Organon LLC | $32.81 | 2022-2023 | Nexplanon |
| Glaxosmithkline, LLC. | $27.37 | 2022-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $22.96 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $22.80 | 2023 | Gardasil 9 |
| Agile Therapeutics, INC. | $17.97 | 2023 | Twirla |
| Coloplast Corp | $15.42 | 2022 | |
| Coopersurgical, INC. | $14.89 | 2021 | |
| Avion Pharmaceuticals | $12.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gretchen Sciarrino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.